Physician profile
Edward Hoang Nam Vo
NPI 1689196891
$154.82
in general payments reported to CMS, 2019-2025
4 companies · $86.48 in 2025
The $86.48 reported for 2025 was less than what a typical Obesity Medicine (Preventive Medicine) provider received nationally (typical 2025 total: $203).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $68.34 · 2025: $86.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $96.58 | 2024-2025 | Wegovy |
| Rhythm Pharmaceuticals, INC. | $28.13 | 2025 | Imcivree |
| Corcept Therapeutics | $15.21 | 2025 | Korlym |
| Lilly USA, LLC | $14.90 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.